Allergy and Immunology Review Corner: Chapter 19 of Immunology IV: Clinical Applications in Health and Disease, by Joseph A. Bellanti, MD.

Similar documents
DNA vaccine, peripheral T-cell tolerance modulation 185

Immunological Tolerance

Immunology Lecture 4. Clinical Relevance of the Immune System

Immune Tolerance. Kyeong Cheon Jung. Department of Pathology Seoul National University College of Medicine

Allergy and Immunology Review Corner: Chapter 13 of Immunology IV: Clinical Applications in Health and Disease, by Joseph A. Bellanti, MD.

Tumor Microenvironment and Immune Suppression

Lecture outline. Immunological tolerance and immune regulation. Central and peripheral tolerance. Inhibitory receptors of T cells. Regulatory T cells

T-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes:

T-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes:

Immune Regulation and Tolerance

Central tolerance. Mechanisms of Immune Tolerance. Regulation of the T cell response

Mechanisms of Immune Tolerance

SEVENTH EDITION CHAPTER

Adaptive immune responses: T cell-mediated immunity

Autoimmunity. Autoimmunity arises because of defects in central or peripheral tolerance of lymphocytes to selfantigens

General Overview of Immunology. Kimberly S. Schluns, Ph.D. Associate Professor Department of Immunology UT MD Anderson Cancer Center

Tolerance 2. Regulatory T cells; why tolerance fails. Abul K. Abbas UCSF. FOCiS

Darwinian selection and Newtonian physics wrapped up in systems biology

Immune responses in autoimmune diseases

5% of patients with genetic immunodeficiency develop a cancer during their lifetime (200x)

FOCiS. Lecture outline. The immunological equilibrium: balancing lymphocyte activation and control. Immunological tolerance and immune regulation -- 1

Effector mechanisms of cell-mediated immunity: Properties of effector, memory and regulatory T cells

ACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS. Choompone Sakonwasun, MD (Hons), FRCPT

Objectives. Abbas Chapter 11: Immunological Tolerance. Question 1. Question 2. Question 3. Definitions

Immunology for the Rheumatologist

S. No Topic Class No Date

Basic Immunology. Immunological tolerance. Cellular and molecular mechanisms of the immunological tolerance. Lecture 23 rd

Immune surveillance hypothesis (Macfarlane Burnet, 1950s)

Tolerance 2. Regulatory T cells; why tolerance fails. FOCiS. Lecture outline. Regulatory T cells. Regulatory T cells: functions and clinical relevance

T cell maturation. T-cell Maturation. What allows T cell maturation?

Tolerance, autoimmunity and the pathogenesis of immunemediated inflammatory diseases. Abul K. Abbas UCSF

Development of B and T lymphocytes

CELL BIOLOGY - CLUTCH CH THE IMMUNE SYSTEM.

Bihong Zhao, M.D, Ph.D Department of Pathology

Allergy and Immunology Review Corner: Chapter 1 of Immunology IV: Clinical Applications in Health and Disease, by Joseph A. Bellanti.

Chapter 23 Immunity Exam Study Questions

5/1/13. The proportion of thymus that produces T cells decreases with age. The cellular organization of the thymus

Effector T Cells and

Primer on Tumor Immunology. International Society for Biological Therapy of Cancer. C. H. June, M.D. November 10, 2005

Basic Principles of Tumor Immunotherapy and Mechanisms of Tumor Immune Suppression. Bryon Johnson, PhD

Tumors arise from accumulated genetic mutations. Tumor Immunology (Cancer)

COURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16

Principles of Adaptive Immunity

Improving cancer immunotherapy by targeting tumorinduced immune suppression

Advances in Cancer Immunotherapy

The Adaptive Immune Responses

I. Defense Mechanisms Chapter 15

Disruption of Healthy Tissue by the Immune Response Autoimmune diseases: Inappropriate immune response against self-components

1. The scavenger receptor, CD36, functions as a coreceptor for which TLR? a. TLR ½ b. TLR 3 c. TLR 4 d. TLR 2/6

Antigen Presentation and T Lymphocyte Activation. Abul K. Abbas UCSF. FOCiS

T Lymphocyte Activation and Costimulation. FOCiS. Lecture outline

1. Overview of Adaptive Immunity

Cytokines modulate the functional activities of individual cells and tissues both under normal and pathologic conditions Interleukins,

CHAPTER 9 BIOLOGY OF THE T LYMPHOCYTE

Adaptive Immunity: Specific Defenses of the Host

Medical Virology Immunology. Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University

What is Autoimmunity?

What is Autoimmunity?

The Immune System: Innate and Adaptive Body Defenses Outline PART 1: INNATE DEFENSES 21.1 Surface barriers act as the first line of defense to keep

Tumor Immunology. Wirsma Arif Harahap Surgical Oncology Consultant

LESSON 2: THE ADAPTIVE IMMUNITY

Attribution: University of Michigan Medical School, Department of Microbiology and Immunology

LYMPHOCYTES & IMMUNOGLOBULINS. Dr Mere Kende, Lecturer SMHS

The Lymphatic System and Body Defenses

T Cell Activation. Patricia Fitzgerald-Bocarsly March 18, 2009

Chapter 35 Active Reading Guide The Immune System

Examples of questions for Cellular Immunology/Cellular Biology and Immunology

ACTIVATION OF T LYMPHOCYTES AND CELL MEDIATED IMMUNITY

Chapter 1. Chapter 1 Concepts. MCMP422 Immunology and Biologics Immunology is important personally and professionally!

Mucosal Immune System

Diseases of Immunity 2017 CL Davis General Pathology. Paul W. Snyder, DVM, PhD Experimental Pathology Laboratories, Inc.

The Adaptive Immune Response: T lymphocytes and Their Functional Types *

The development of T cells in the thymus

Third line of Defense

T Cell Receptor & T Cell Development

Cytokine Arrays Reveal Black Ops Tactics of Tumor-induced Immunosuppression

CANCER IMMUNOPATHOLOGY. Eryati Darwin Faculty of Medicine Andalas University

Mon, Wed, Fri 11:00 AM-12:00 PM. Owen, Judy, Jenni Punt, and Sharon Stranford Kuby-Immunology, 7th. Edition. W.H. Freeman and Co., New York.

Self Tolerance and MHC Restriction. Dr. Issa Abu-Dayyeh

COURSE: Medical Microbiology, MBIM 650/720 - Fall TOPIC: Antigen Processing, MHC Restriction, & Role of Thymus Lecture 12

The Immune System. Innate. Adaptive. - skin, mucosal barriers - complement - neutrophils, NK cells, mast cells, basophils, eosinophils

Immune Checkpoints. PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich

T Cell Activation, Costimulation and Regulation

Physiology Unit 3. ADAPTIVE IMMUNITY The Specific Immune Response

Defensive mechanisms include :

Determinants of Immunogenicity and Tolerance. Abul K. Abbas, MD Department of Pathology University of California San Francisco

Cell-mediated Immunity

All animals have innate immunity, a defense active immediately upon infection Vertebrates also have adaptive immunity

Immunology MIMM-314 MID-TERM II EXAMINATION. 1 hour between 8:30 a.m. - 10:00 a.m. McIntyre Medical Rm 504 (Martin Amphitheatre)

T cell-mediated immunity

The Immune System. by Dr. Carmen Rexach Physiology Mt San Antonio College

AUTOIMMUNITY CLINICAL CORRELATES

AUTOIMMUNITY TOLERANCE TO SELF

Third line of Defense. Topic 8 Specific Immunity (adaptive) (18) 3 rd Line = Prophylaxis via Immunization!

Respuesta inmune anti-tumoral. Aura Muntasell Institut Hospital del Mar d Investigacions Mèdiques Parc de Recerca Biomèdica de Barcelona

BASIC MECHANISM OF TUMOR IMMUNE SUPPRESSION

Chapter 21 The Immune System: Innate and Adaptive Body Defenses

IMMUNOTHERAPY FOR CANCER A NEW HORIZON. Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust

The Immune System. A macrophage. ! Functions of the Immune System. ! Types of Immune Responses. ! Organization of the Immune System

Chapter 24 The Immune System

Transcription:

Allergy and Immunology Review Corner: Chapter 19 of Immunology IV: Clinical Applications in Health and Disease, by Joseph A. Bellanti, MD. Chapter 19: Tolerance, Autoimmunity, and Autoinflammation Prepared by Meagan W. Shepherd, MD, Ohio State University 1. Which of the following terms refers to a specific immunological unresponsiveness to an antigen resulting from a previous exposure to the same antigen? A. Antigenicity B. Tolerance C. Allergenicity D. Immunodeficiency 2. Anergy refers to which of the following? A. T cell clones that are unable to respond to an antigenic stimulus B. B cells that are unable to produce immunoglobulin C. Induction of double negative T cells upon exposure to stimulus D. Activation of the Fas pathway 3. Which of the following molecules has the highest affinity when binding with CD80/86? A. MHC-I B. MHC-II C. CD28 D. CTLA-4 4. Which of the following diseases can be caused by a mutation to the Fas or Fas ligand gene? A. X-linked lymphoproliferative syndrome B. Severe combined immunodeficiency (SCID) C. Autoimmune lymphoproliferative syndrome (ALPS) D. Wiskott-Aldrich syndrome 5. Which of the following cytokines are the most important in suppressing the immune response? A. IL-3 and IL-5 B. IFN-gamma and IL-1 C. IL-2 and IL-4 D. TNF-β and IL-10 6. Autoimmune Polyglandular Syndrome Type I (APS-1) is caused by a mutation or absence of which of the following? A. Autoimmune regulator (AIRE) B. Fas C. WASp protein

D. STAT 3 7. Which of the following is the proposed self-antigen in Wegener s granulomatosis? A. Thyrotropin receptor B. Nuclear antigens (SSA, SSB) C. Proteinase 3 (c-anca) D. Citrulinated peptides in the joint, IgG 8. Which of the following MHC-associations is found with multiple sclerosis? A. HLA-B27 B. HLA-DR2 C. HLA-DR4 D. HLA-B13 9. Which of the following drugs is not implicated in causing high rates of drug-induced lupus erythematosus? A. Hydralazine B. Amoxicillin C. Procainamide D. Isoniazid 10. True or False: B cells that bear receptors capable of recognizing self-antigens are all eliminated in the bone marrow? Answers 1. B, page 769 One of the most important immunologic principles required for an understanding of autoimmunity and autoimmune disease is the concept of tolerance, which refers to specific immunological unresponsiveness to an antigen resulting from a previous exposure to the same antigen. 2. A, page 773 One of the major mechanisms that the human body uses to inactivate self-reactive T cell clones that have escaped central and peripheral clonal deletion is anergy. By definition, anergy refers to T cell clones that are unable to respond to an antigenic stimulus. 3. D, page 774 CTLA-4, a homologue of CD28, also binds the CD80/86 ligands, but with greater affinity than CD28, resulting in the inhibition and negative regulation of T cell activation. MHC molecules do not bind with CD80/86. 4. C, page 773 There is another rare human disease called autoimmune lymphoproliferative syndrome (ALPS) that is caused by mutations similar to the lpr mouse mutations in either the Fas or Fas ligand gene (termed ALPS 1a and 1b respectively). Patient with these mutations have significant lymphadenopathy and also produce an array of autoantibodies.

5. D, page 775 The reactivity of T cells is under the influence of immunoregulatory cells either through direct cell-cell interaction or through the secretion of cytokines, e.g. transforming growth factor (TGF)-β and IL-10. 6. A, page 770 T cells that recognize autoantigens on the surface of the thymic epithelial cells undergo apoptosis, thus preventing peripheral autoimmunity. These autoantigens are proteins derived from a diversity of tissues and organs and are expressed on the thymic epithelial cells at least partly under the regulation of the transcription factor autoimmune regulator (AIRE). 7. C, page 779, Table 19-2 Wegener s granulomatosis is thought to be caused by self-antigens to proteinase 3 (c- ANCA). 8. B, page 781, Table 19-4 Multiple sclerosis is associated with HLA-DR2. 9. B, page 782 Of the thirty medications known to cause drug-induced lupus, the three that most commonly cause the condition are hydralazine, procainamide, and isoniazid. 10. False, page 777 although B-cell receptor rearrangement in the bone marrow is similar to T-cell receptor rearrangement, B cells that bear receptors capable of recognizing self-antigens are not necessarily eliminated in the bone marrow through negative selection. Some of these still-maturing self-reactive B cells exit the bone marrow and relocate peripherally to the spleen, where they reside initially in T cell zones. Allergy and Immunology Review Corner: Chapter 20 of Immunology IV: Clinical Applications in Health and Disease, by Joseph A. Bellanti, MD. Chapter 20: Immune Responses to Cancer Prepared by Monica Bhagat, MD, University of Pennsylvania 1. There are four groups of peptides that classify as TATAs (TAAs) or tumor-associated transplantion antigens. Which of the following is not representative of these four groups? A. Unique tumor-specific antigens B. Over-expressed self-antigen peptides/proteins C. Shared tumor antigens D. Bacterial-associated antigens 2. Which of the following innate immune cells play a key role in tumor immunity by

taking up tumor antigens and migrate to lymphoid organs where presentation of processed peptides to T cells occurs? A. Mast cells B. NK cells C. DCs D. Basophils 3. Antibodies can play a direct role in KILLING tumor cells via the activation of what key component of the innate immune system? A. Membrane-attack complex (MAC) B. Dendritic cells C. Mast cells D. Basophils 4. Which of the following is an example of a previously suppressed embryonic antigen? A. CEA B. MAGE tumor-associated antigen C. HPV D. P53 5. The following homeostatic immune actions are favored in the premalignant state by TGF-B EXCEPT: A. Apoptosis of premalignant cells B. Downregulation of tumorigenic inflammation C. Cytostasis D. Inhibition of effector cells 6. Which of the following is FALSE regarding the enzyme Indoleamine-2,3 dioxygenase (IDO)? A. It converts tryptophan to kynurenine B. It is only produced by mast cells C. It plays a role in the inactivation of the tumor suppressor gene Bin1 D. It is upregulated in plasmacytoid DCs leading to the activation of Tregs 7. In pathological differentiation of myeloid cells, immature myeloid cells may differentiate into myeloid-derived suppressor cells (MDSCs). These MDSCs express which of the following immune suppressive factors? A. Arginase 1 B. inos C. ROS D. All of the above 8. T regulatory cells are crucial in cancer immunology, in the sense that regulatory T cell mediated immunosuppression is one of the most crucial tumor immune-evasion mechanisms. Which of the following subset of Treg cells is INCORRECTLY identified by its marker?

A. Natural Treg (ntreg) = CD4+CD25+FOXP3+ B. Induced Treg (itreg) = CD4+IL10+FOXP3+ C. TH3 cells = CD4+TGF-B+ D. d. TR1 cells = CD4-CD25+FOXP3+ 9. In conventional immunotherapy, one can aim to mimic cytokines or block cytokines and/or inhibit their particular pathway. Out of the following cytokines, which one do scientists aim to INHIBIT? A. TGF-beta B. IL-5 C. IFN-alpha D. IL-7 10. Which of the following monoclonal antibodies is INCORRECTLY paired with its target? A. Cetuximab and EGFR B. Trastuzumab and HER2 C. Bevacizumab and VEGF D. Canakinumab and IL-12 Answers 1. D, page 802, Table 20-1 Viral-associated antigens make up the fourth category of TAAs and include HPV, HBV, and EBV. 2. C, page 806 Dendritic cells play a crucial role in the interface between innate immunity and adaptive immunity via such presentation of processed peptides to T cells. Mast cells, macrophages, and even the DCs may be considered sentinel cells that are pre-stationed in tissue where they continuously monitor the microenvironment. 3. A, page 812 Antibody directed to TAA together with the activation of the complement systemc can kill the cancer cell by cytolytic activation of the MAC cascade. However, alternatively, TAA complexed with antibodies as Ag-Ab complexes can interfere with the CTL-killing of a cancer cell by blocking its activity. So antibodies directed against TAAs can either facilitate the killing of tumor cells or paradoxically enhance their growth. 4. A, page 802-803, Table 20-1 CEA is a type of tumor antigen that is a part of the category called overexpressed self antigen peptides. These include CEA and Muc-1 (colorectal cancer), Her-2/neu (breast cancer), and EGF receptor (colorectal, lung, head, and neck cancers). MAGE is shared among different tumors and is in the shared tumor antigen category, HPV is in the viral-associated antigen category, and p53 is part of the unique tumor-specific antigen category.

5. D, page 820. Fig 20-21 TGF-B inhibits immune effector cells in the malignant progression stage, when TGF-B is functioning as a tumor promoter. TGF-B is considered a tumor supporter during the metastasis stage. 6. B, page 816 IDO is a key enzyme that converts Trp to Kyn and is involved in tumor growth and immune suppression. It does this by inactivating Bin1 and via the activation of Treg cells and blunting of T effector cell function. It is produced by alternatively activated macrophages and other immunoregulatory cells. 7. D, pages 818-819 In the setting of infection, trauma, immunosuppression, or autoimmunity, a partial block in IMC differentiation results in their abnormal expansion. Such pathologic conditions can then lead to the differentiation into MDSCs which produce STAT-induced arginase 1, inos, and ROS. MDSCs are defined as CD14-CD11b+ cells that express CD33 but lack expression of markers found on mature cells. Key to note is that in response to tumor derived factors, the MDSCs will differentiate into TAMs (tumor-associated macrophages) which contributes to non-specific T cell suppression. 8. D, page 811, Table 20-3. T regulatory 1 cells, or TR1 cells, are synonymous with induced Treg cells (itreg). TR1 cells are CD4+IL- 10+FOXP3+. Recall that there are CD4+ based Treg cells and CD8+ Treg cells. Some arise in the thymus, like the ntreg cells, while others arise in the periphery, like the itreg and CD8+IL-10+ Treg cells. 9. A, page 822, Table 20-4 IFN-alpha, along with IL-5, IL-7, and IL-21 have all been studied extensively by seeing if trial administration of such cytokines or recombinant forms of such cytokines can lead to the destruction of cancerous cells. The toxicity of utilizing interferons in general, however, has limited the use of recombinant IFN-alpha. TGF-B plays a pivotal role in tumor development, functioning as a tumor suppressor in the pre-malignant state and evolving to function as tumor promoter and eventually tumor supporter in the metastatic stage. Consequently, research is focused on antagonism of TGF-beta. 10. D, page 821, Table 20-5 Canakinumab targets IL-1 beta and was approved by the FDA in 2009 for use in CAPS (cryopyrin-associated periodic syndromes).